Congratulations to the team at Alesta Therapeutics on raising an impressive €65 million in their Series A financing! Led by Frazier Life Sciences and Droia Ventures, this round will push their work in rare disease therapies to new levels.
Their lead program, ALE1, targets hypophosphatasia (HPP), a rare genetic disorder, with plans to enter clinical trials in 2025. With a second program addressing Charcot-Marie-Tooth (CMT), Alesta is on a mission to transform patient care in underserved areas.
This milestone shows how innovative science, dedicated leadership, and collaboration with global experts lead to impactful results.
We’re excited to see how this funding accelerates their work to deliver life-changing therapies. And we’re proud to see a company in our community thrive on its journey to make a difference in patients’ lives globally.
Huge congrats to the Alesta team and their partners for this incredible achievement!
Read the full press release here
University Campus Spui, Leiden University’s fourth location in The Hague, is about to open its doors. The transformation of the former V&D department store into a university...
Biotech start-up Bionomic from Oegstgeest (South Holland) won the Innovation Promise Award on Friday during the twentieth edition of the announcement of the KVK Innovation Top...
The Dutch Life Sciences Conference 2025 was held on 20 November 2025 at the CORPUS Congress Centre in Oegstgeest, bringing together biotech and medtech companies, academic...